Skip to main content
Signal8
Launch Terminal

ARS Pharmaceuticals, Inc. (SPRY)

ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

ARS Pharmaceuticals, Inc. logo

ARS Pharmaceuticals, Inc.

NASDAQ:SPRYHealthcare
-7.65%$3.38
AH$3.44+1.78%vs close
Mkt Cap$336.13M
Float48.99M
O/S99.45M
Vol
$ Vol
RVOL
Inst Own91.2%
SI40.5%
Earnings
Dilution
ARS Pharmaceuticals, Inc. logoNASDAQ:SPRY$3.38-7.65%
Phase Distribution
8 lead-sponsored trials·2 active·3 completed
Phase 12
Phase 1/22
Phase 23
Phase 41
(2 more as collaborator)
Status Overview
Recruiting2
Completed3
Stopped2
Unknown1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 4
    Recruiting

    Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy

    Neffy, Adrenaline

    Allergic Reactions

    Enrollment
    600
    Start
    May 2025
    Primary Completion
    Apr 2027est.
    Completion
    Jun 2027est.
    NCT06834165
  • Phase 2
    Completed

    Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma

    ARS-1 1 mg, Albuterol MDI

    Asthma

    Enrollment
    18
    Start
    Jul 2022
    Primary Completion
    Feb 2024
    Completion
    Feb 2024
    NCT05363670
  • Phase 2
    Completed

    Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria Flares

    ARS-1

    Urticaria

    Enrollment
    21
    Start
    Jul 2022
    Primary Completion
    Feb 2024
    Completion
    Feb 2024
    NCT05496465
  • Phase 2
    Recruiting

    An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria

    Placebo, 0.5 mg epinephrine

    Urticaria Chronic

    Enrollment
    42
    Start
    Jul 2025
    Primary Completion
    Jun 2027est.
    Completion
    Jun 2027est.
    NCT06927999
  • Phase 1/2
    Terminated

    A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

    SBT6050, trastuzumab deruxtecan

    HER2-positive Breast Cancer, HER2-positive Gastric Cancer +2

    Enrollment
    2
    Start
    Feb 2022
    Primary Completion
    Jul 2022
    Completion
    Jul 2022
    NCT05091528
  • Phase 1/2
    Withdrawn

    A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors

    SBT6290, SBT6290

    Urothelial Carcinoma, Triple Negative Breast Cancer +3

    Enrollment
    0
    Start
    Mar 2022est.
    Primary Completion
    Mar 2022
    Completion
    Mar 2022
    NCT05234606
  • Phase 1
    Unknown status

    A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

    SBT6050, pembrolizumab

    HER2 Positive Solid Tumors

    Enrollment
    58
    Start
    Jul 2020
    Primary Completion
    Dec 2022est.
    Completion
    Dec 2022est.
    NCT04460456
  • Phase 1
    Completed

    Pharmacokinetics of Adrenaline After Administration of ARS -1 in Subjects With Upper Respiratory Tract Infection

    ARS-1 with URTI, ARS-1 without URTI

    Upper Respiratory Tract Infection

    Enrollment
    15
    Start
    Aug 2021
    Primary Completion
    Mar 2022
    Completion
    Jul 2022
    NCT04930900
Search ClinicalTrials.gov for “ARS Pharmaceuticals”